Published in J Clin Oncol on January 25, 2016
T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma. Blood (2016) 1.72
CD19-targeted CAR T-cell therapeutics for hematologic malignancies: interpreting clinical outcomes to date. Blood (2016) 1.10
Toxicities of chimeric antigen receptor T cells: recognition and management. Blood (2016) 1.07
Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells. Sci Transl Med (2016) 1.01
Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells. J Clin Invest (2016) 0.96
Clinical manufacturing of CAR T cells: foundation of a promising therapy. Mol Ther Oncolytics (2016) 0.93
Predominant cerebral cytokine release syndrome in CD19-directed chimeric antigen receptor-modified T cell therapy. J Hematol Oncol (2016) 0.88
Generation of clinical-grade CD19-specific CAR-modified CD8+ memory stem cells for the treatment of human B-cell malignancies. Blood (2016) 0.86
Review: Current clinical applications of chimeric antigen receptor (CAR) modified T cells. Cytotherapy (2016) 0.85
The Principles of Engineering Immune Cells to Treat Cancer. Cell (2017) 0.85
Donor CD19 CAR T cells exert potent graft-versus-lymphoma activity with diminished graft-versus-host activity. Nat Med (2017) 0.84
Chimeric antigen receptor-modified T cells for the treatment of solid tumors: Defining the challenges and next steps. Pharmacol Ther (2016) 0.82
Chimeric antigen receptors: driving immunology towards synthetic biology. Curr Opin Immunol (2016) 0.81
Long-Duration Complete Remissions of Diffuse Large B Cell Lymphoma after Anti-CD19 Chimeric Antigen Receptor T Cell Therapy. Mol Ther (2017) 0.80
Diffuse Large B-Cell Lymphoma with Primary Treatment Failure: Ultra-high Risk Features and Benchmarking for Experimental Therapies. Am J Hematol (2016) 0.79
Co-infusion of haplo-identical CD19-chimeric antigen receptor T cells and stem cells achieved full donor engraftment in refractory acute lymphoblastic leukemia. J Hematol Oncol (2016) 0.79
Chimeric Antigen Receptor T Cells and Hematopoietic Cell Transplantation: How Not to Put the CART Before the Horse. Biol Blood Marrow Transplant (2016) 0.78
Optimization of peptide vaccines to induce robust antitumor CD4 T-cell responses. Cancer Immunol Res (2016) 0.77
Therapeutic T cell engineering. Nature (2017) 0.77
A novel TCR-like CAR with specificity for PR1/HLA-A2 effectively targets myeloid leukemia in vitro when expressed in human adult peripheral blood and cord blood T cells. Cytotherapy (2016) 0.76
Engineering Natural Killer Cells for Cancer Immunotherapy. Mol Ther (2017) 0.76
Immunotherapy in hematologic malignancies: past, present, and future. J Hematol Oncol (2017) 0.75
CARs: Synthetic Immunoreceptors for Cancer Therapy and Beyond. Trends Mol Med (2017) 0.75
Anti-CD19 chimeric antigen receptor T-cell therapy for adult Philadelphia chromosome-positive acute lymphoblastic leukemia: Two case reports. Medicine (Baltimore) (2016) 0.75
Life after transplant: are we becoming high maintenance in AML? Bone Marrow Transplant (2016) 0.75
Third-generation CD28/4-1BB chimeric antigen receptor T cells for chemotherapy relapsed or refractory acute lymphoblastic leukaemia: a non-randomised, open-label phase I trial protocol. BMJ Open (2016) 0.75
Elutriated lymphocytes for manufacturing chimeric antigen receptor T cells. J Transl Med (2017) 0.75
Redirecting T-cells to eradicate B-cell acute lymphoblastic leukemia: Bispecific T-cell engagers and chimeric antigen receptors. Leukemia (2016) 0.75
The Flipside of the Power of Engineered T Cells: Observed and Potential Toxicities of Genetically Modified T Cells as Therapy. Mol Ther (2017) 0.75
Antigen receptor-redirected T cells derived from hematopoietic precursor cells lack expression of the endogenous TCR/CD3 receptor and exhibit specific antitumor capacities. Oncoimmunology (2017) 0.75
Exhausting alloreactivity of donor-derived CAR T cells. Nat Med (2017) 0.75
Recent advances in T-cell engineering for use in immunotherapy. F1000Res (2016) 0.75
PD-L1 serves as a double agent in separating GVL from GVHD. J Clin Invest (2017) 0.75
Allogeneic CD19-CAR-T cell infusion after allogeneic hematopoietic stem cell transplantation in B cell malignancies. J Hematol Oncol (2017) 0.75
Chimeric Antigen Receptor (CAR) T Cells: Lessons Learned from Targeting of CD19 in B-Cell Malignancies. Drugs (2017) 0.75
Next-Generation Chimeric Antigen Receptor T-Cell Therapy: Going off the Shelf. BioDrugs (2017) 0.75
Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature (1999) 34.47
1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant (1995) 24.01
Revised response criteria for malignant lymphoma. J Clin Oncol (2007) 22.19
National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant (2005) 19.83
Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med (2011) 18.99
T cell exhaustion. Nat Immunol (2011) 11.08
PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature (2014) 10.39
Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med (2014) 8.21
Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells. J Exp Med (2005) 8.13
CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med (2013) 7.99
Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood (2010) 7.25
Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15. Nat Med (2003) 6.81
Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med (2014) 5.60
T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet (2014) 5.42
Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood (1995) 5.34
Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc Natl Acad Sci U S A (1993) 5.23
Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J Clin Oncol (2014) 3.94
Graft-versus-leukemia effects of transplantation and donor lymphocytes. Blood (2008) 3.85
T-cell clones can be rendered specific for CD19: toward the selective augmentation of the graft-versus-B-lineage leukemia effect. Blood (2002) 3.57
Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation. Blood (2013) 3.45
Current concepts in the diagnosis and management of cytokine release syndrome. Blood (2014) 2.63
Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells. Blood (2010) 2.52
Construction and preclinical evaluation of an anti-CD19 chimeric antigen receptor. J Immunother (2009) 2.35
Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study. Blood (2013) 2.13
Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors. Nat Rev Clin Oncol (2013) 1.91
Favorable long-term survival after reduced-intensity allogeneic transplantation for multiple-relapse aggressive non-Hodgkin's lymphoma. J Clin Oncol (2008) 1.64
NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: report from the Committee on the Epidemiology and Natural History of Relapse following Allogeneic Cell Transplantation. Biol Blood Marrow Transplant (2010) 1.56
Relapse after allogeneic hematopoietic cell therapy. Biol Blood Marrow Transplant (2009) 1.27
Donor lymphocyte infusion following allogeneic hematopoietic stem cell transplantation. Expert Opin Biol Ther (2011) 1.24
Dissecting graft-versus-leukemia from graft-versus-host-disease using novel strategies. Tissue Antigens (2013) 1.22
Chimeric antigen receptor (CAR)-specific monoclonal antibody to detect CD19-specific T cells in clinical trials. PLoS One (2013) 1.14
Graft-versus-host disease after donor leukocyte infusions: presentation and management. Best Pract Res Clin Haematol (2008) 1.07
CD19 chimeric antigen receptor T cell therapy for haematological malignancies. Br J Haematol (2015) 0.93
Allogeneic chimeric antigen receptor-modified cells for adoptive cell therapy of cancer. Expert Opin Biol Ther (2014) 0.92
Next-generation leukemia immunotherapy. Blood (2011) 0.90
Nonmyeloablative allogeneic stem cell transplantation for non-hodgkin lymphoma. Cancer J (2012) 0.89